Rewards That Help Pay for Future Vet Care

IMPORTANT SAFETY INFORMATION: Do not use Apoquel in dogs less than 12 months of age or those with serious infections. Apoquel may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. New neoplastic conditions (benign and malignant) were observed in clinical studies and post-approval. Apoquel has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporines. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. Apoquel has been used safely with many common medications including parasiticides, antibiotics and vaccines. For more information, please see the full Prescribing Information.

INDICATIONS: Control of pruritus (itching) associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

*Based on survey data from veterinarians (n=251) and pet owners (n=552).


  1. ZMR: GAH-284 Unique Patients Since Launch with Growth Rate June 2022
  2. Data on file, APOQUEL/CYTOPOINT Pet Tracker Wave 9, 2021, Zoetis Inc.
  3. Data on file, APOQUEL/CYTOPOINT Vet Tracker Wave 13, 2020, Zoetis Inc.
  4. Gonzales AJ, Bowman JW, Fici G, et al. Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. 2014;37(4):317-324.
APQ-00679R9 | ZPR-00175R2